
    
      The study contains 2 cohorts. Cohort A is the de-escalation cohort. Patients with certain
      HER-positive or HER2-low advanced solid tumors will be enrolled in this cohort. Cohort B is
      the expansion cohort, in which only patients with HER2-positive or HER2-low breast cancer
      will be enrolled.
    
  